Status
Conditions
About
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients.
The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy.
All patients followed at the Montpellier CF center will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up
Full description
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients.
According to our hypothesis, the lung microbiota shapes the lung environment of cystic fibrosis patients and modifies the effectiveness of antibiotic treatments and the course of the disease. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy. Finally, the management of first colonisations could justify the characterisation of the microbiota in order to develop innovative diagnostic tests for the follow-up of patients suffering from cystic fibrosis and possibly the identification of new therapeutic agents based on the microbiota.
All patients followed at the Montpellier CF centre will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion criteria:
Exclusion criteria
Loading...
Central trial contact
Alexandre COUDRAT; Raphael CHIRON, PU-PH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal